Journal: Cancers

Article Title: How Should We Test for Lynch Syndrome? A Review of Current Guidelines and Future Strategies

doi: 10.3390/cancers13030406

Figure Lengend Snippet: Estimated frequency of Lynch syndrome (LS) among unselected patients of different Lynch-spectrum, and other, tumour types. Unselected means no selection of patient by clinical features, such as age or family history. However, some studies selected patients for germline MMR gene testing by tumour MMR deficiency testing.

Article Snippet: , 13/13 (100.0%)/10/10 (100.0%) , MSI by FLA of 2 monoNRs and 3 diNRs (Bethesda panel)/IHC of MLH1, MSH2, and MSH6 , Gylling et al., 2008 [ ] .

Techniques: Selection, Methylation, Biomarker Discovery

Journal: Cancers

Article Title: How Should We Test for Lynch Syndrome? A Review of Current Guidelines and Future Strategies

doi: 10.3390/cancers13030406

Figure Lengend Snippet: Estimated frequency of mismatch repair (MMR) deficiency in different tumour types from Lynch syndrome (LS) gene carriers. Studies were only included if the LS diagnosis was made independent of tumour MMR status.

Article Snippet: , 13/13 (100.0%)/10/10 (100.0%) , MSI by FLA of 2 monoNRs and 3 diNRs (Bethesda panel)/IHC of MLH1, MSH2, and MSH6 , Gylling et al., 2008 [ ] .

Techniques: Biomarker Discovery

Journal: Cancers

Article Title: How Should We Test for Lynch Syndrome? A Review of Current Guidelines and Future Strategies

doi: 10.3390/cancers13030406

Figure Lengend Snippet: Estimated frequency of mismatch repair (MMR) deficiency among unselected tumours of different Lynch-spectrum, and other, tumour types. Unselected means no selection of tumours by the patients’ clinical features, such as age or family history.

Article Snippet: , 13/13 (100.0%)/10/10 (100.0%) , MSI by FLA of 2 monoNRs and 3 diNRs (Bethesda panel)/IHC of MLH1, MSH2, and MSH6 , Gylling et al., 2008 [ ] .

Techniques: Selection, Southern Blot, Marker

Journal: BMC Endocrine Disorders

Article Title: Targeting syndecan-2 inhibits papillary thyroid cancer invasiveness and de-differentiation

doi: 10.1186/s12902-025-02055-3

Figure Lengend Snippet: SDC2 expression in pan-caner databases and PTC cell lines. A SDC2 transcription levels in all the 32 TCGA cancer cohorts. (B, C) Expression levels of SDC2 in 502 PTC tissues than that in adjacent 58 normal tissues from TGCA-THCA cohort (unpaired or paired test). D , E Expression levels of SDC2 in GSE29265 (29 PTCs and paired normal thyroid tissues) and GSE33630 (45 PTCs and paired normal thyroid tissues) (paired test). F Representative immunohistological staining of SDC2 image in PTC tumor tissue and normal thyroid tissue from Human Protein Atlas. G Representative western-blotting pictures of SDC2 protein level in different PTC cell lines. Unpaired or paired t test, * P < 0.05, *** P < 0.001

Article Snippet: F Representative immunohistological staining of SDC2 image in PTC tumor tissue and normal thyroid tissue from Human Protein Atlas.

Techniques: Expressing, Staining, Western Blot

Journal: BMC Endocrine Disorders

Article Title: Targeting syndecan-2 inhibits papillary thyroid cancer invasiveness and de-differentiation

doi: 10.1186/s12902-025-02055-3

Figure Lengend Snippet: Clinical significance of the SDC2 expression in TCGA-THCA cohort. A - D The distribution of the SDC2 expression level according to different status of age, T stage, N stage and AJCC stage in the TCGA-THCA dataset. E - H The distribution of the SDC2 expression level according to different status of recurrence status, histological type, residual tumor and extrathyroidal invasion in the TCGA-THCA dataset. I , J K-M analysis investigating the prognostic value of SDC2 expression in the PTC patients from TCGA-THCA cohort with different outcome (PFI or OS). K , L Univariate and multivariate Cox regression analysis for identification of independent prognostic factor enrolling SDC2 expression. * P < 0.05 **** P < 0.0001

Article Snippet: F Representative immunohistological staining of SDC2 image in PTC tumor tissue and normal thyroid tissue from Human Protein Atlas.

Techniques: Expressing

Journal: BMC Endocrine Disorders

Article Title: Targeting syndecan-2 inhibits papillary thyroid cancer invasiveness and de-differentiation

doi: 10.1186/s12902-025-02055-3

Figure Lengend Snippet: knockdown or overexpression of SDC2 altered EMT process in PTC cells. A , C Western-blotting analysis of knockdown effects of 3 pairs of pre-designed SDC2 siRNA and siNC in BCPAP cells. B , D overexpress effect of pre-designed SDC2 plasmid transfection in KTC-1 cells. E - H EMT markers including ZO-1 and a-SMA were measured and compared in BCPAP and KTC-1 cells, n = 3. Unpaired t test, * P < 0.05 ** P < 0.01

Article Snippet: F Representative immunohistological staining of SDC2 image in PTC tumor tissue and normal thyroid tissue from Human Protein Atlas.

Techniques: Knockdown, Over Expression, Western Blot, Plasmid Preparation, Transfection

Journal: BMC Endocrine Disorders

Article Title: Targeting syndecan-2 inhibits papillary thyroid cancer invasiveness and de-differentiation

doi: 10.1186/s12902-025-02055-3

Figure Lengend Snippet: Alteration of SDC2 affects PTC cells migration, invasion, and viability. Representative images and results of scratch wound-healing assays plates in B-CPAP cells ( A ) and in KTC-1 cells ( B ) with different treatments in each timepoints, line graph indicating related wound areas. Representative images and results of transwell assays plates in B-CPAP cells ( C ) and in KTC-1 cells ( D ) with different treatments in each timepoints, bar plots indicating infiltrated cell numbers. Bar plot of relative OD value indicating the cell viability with different treatments or timepoints in B-CPAP cells ( E ) and in KTC-1 cells F . Unpaired t test, * P < 0.05 ** P < 0.01

Article Snippet: F Representative immunohistological staining of SDC2 image in PTC tumor tissue and normal thyroid tissue from Human Protein Atlas.

Techniques: Migration

Journal: BMC Endocrine Disorders

Article Title: Targeting syndecan-2 inhibits papillary thyroid cancer invasiveness and de-differentiation

doi: 10.1186/s12902-025-02055-3

Figure Lengend Snippet: Bioinformatic analysis for SDC2 related genes and pathways prediction. A - C Volcano plot and heatmap showing the positively and negatively related genes with SDC2 expression in TCGA-THCA cohort generated through “LinkFinder” module of LinkedOmics database. D Potential enriched pathway GSEA result in KEGG gene set of SDC2 positively and negatively related genes through “LinkInterpreter” module. E Spearman analyses revealed correlations between SDC2 expression and thyroid differentiation markers

Article Snippet: F Representative immunohistological staining of SDC2 image in PTC tumor tissue and normal thyroid tissue from Human Protein Atlas.

Techniques: Expressing, Generated

Journal: BMC Endocrine Disorders

Article Title: Targeting syndecan-2 inhibits papillary thyroid cancer invasiveness and de-differentiation

doi: 10.1186/s12902-025-02055-3

Figure Lengend Snippet: Relations between SDC2 expression and thyroid differentiation markers in PTC cells. QPCR results of thyrocyte differentiation markers and expression of hedgehog signaling members with SDC2 knockdown or overexpress in BCPAP ( A , C ) and in KTC-1 cells ( B , D ). ( E ) Western-blotting results of TSHR and NIS in BCPAP cells with SDC2 knockdown. N = 3 Unpaired t test, * P < 0.05

Article Snippet: F Representative immunohistological staining of SDC2 image in PTC tumor tissue and normal thyroid tissue from Human Protein Atlas.

Techniques: Expressing, Knockdown, Western Blot